The systemic administration of an agonist antibody against
glucocorticoid-induced
tumor necrosis factor receptor related (GITR)
protein has been shown to be effective in overcoming immune tolerance and promoting
tumor rejection in a variety of murine
tumor models. However, little is known regarding the functional consequence of
ligation of GITR with its natural
ligand (GITR-L) in the context of regulatory T cell (Treg) suppression in vivo. To determine the mechanism of GITR-L action in vivo, we generated a panel of
tumor cell clones that express varying levels of GITR-L. The ectopic expression of GITR-L on the
tumor cell surface was sufficient to enhance anti-
tumor immunity and delay
tumor growth in syngeneic BALB/c mice. Within the range examined, the extent of anti-
tumor activity in vivo did not correlate with the level of GITR-L expression, as all clones tested exhibited a similar delay in
tumor growth. The localized expression of GITR-L on
tumor cells led to a significant increase in CD8+ T cell infiltration compared to the levels seen in control
tumors. The increased proportion of CD8+ T cells was only observed locally at the
tumor site and was not seen in the
tumor draining lymph node. Depletion studies showed that CD8+ T cells, but not CD4+ T cells, were required for GITR-L mediated protection against
tumor growth. These studies demonstrate that signaling between GITR-L and GITR in the tumor microenvironment promotes the infiltration of CD8+ T cells, which are essential for controlling
tumor growth.